#Sustainability #Zentiva #Czech Republic #Prague #Health

Zentiva's 2025 Sustainability Report: A Year of Progress

On March 17, 2026, Zentiva announced the release of its 2025 Sustainability Report, marking another year filled with advancements in public health, environmental stewardship, and responsible business practices. In 2025, the company demonstrated that business growth can coincide with environmental responsibility by reducing greenhouse gas emissions from its operations (Scope 1 and 2 emissions) by 10%, while simultaneously increasing net revenues and EBITDA.

Zentiva's sustainability goals, confirmed by the Science Based Targets Initiative (SBTi), include ambitions to reduce Scope 1, 2, and 3 emissions by 63% by 2034 and aiming for net-zero emissions by 2050. In their report, several key achievements stood out:

• - A whopping 83% of the electricity used across Zentiva's operations comes from renewable sources, with a remarkable 100% in production facilities within the EU.
• - The volume of recycled and reused water nearly doubled from 2021 to 2025.
• - About 47% of waste was reused, recycled, or otherwise diverted from landfills.
• - As part of its reforestation initiatives, over 130,000 trees were planted, and more than 3.5 million bees were adopted to support biodiversity.
• - Over 120 projects focused on 'people and community' were implemented across Europe and India, under the #WeHelpOthers initiative.

Zentiva was honored with a gold medal from EcoVadis, placing its sustainability program among the top 2% in the pharmaceutical industry. Additionally, the company received the 2025 Transparency Award from the EUPD Group for its reports and communication regarding sustainability.

Steffen Saltofte, the CEO of Zentiva, stated, "As one of Europe’s leading manufacturers of off-patent medicines, we bear the responsibility of supporting public health systems while simultaneously reducing our impact on the planet. Each day, millions rely on the affordability, accessibility, and availability of the medicines we produce and deliver."

Ines Windisch, director of corporate affairs and sustainability, added, "Zentiva's Sustainability Report illustrates how our daily operations contribute to healthier communities and a healthier environment. Protecting people and the planet goes hand in hand. Sustainability is a continuous commitment that we must apply every day in all we do."

Zentiva plays a crucial role as a prominent provider and producer of off-patent medicines in Europe, ensuring that people across the continent have access to high-quality, affordable medications they rely on daily. Off-patent medicines account for approximately 70% of all prescriptions but only represent 19% of pharmaceutical spending, making them essential for the accessibility and sustainability of public health systems (IQVIA, 2024).

The company continues to invest in its manufacturing base and sustainability strategies to ensure that patients have reliable access to medicines, both now and in the future. The full 2025 Sustainability Report is available on Zentiva's official website at www.zentiva.com/sustainability.

About Zentiva

Zentiva is dedicated to promoting health and well-being for all generations, focusing on the development, production, and delivery of high-quality, affordable medicines to over 100 million people in more than 40 countries across Europe. The company operates four manufacturing plants and maintains a wide network of external manufacturing partners to safeguard supply security. With over 5,400 unique talents employed in more than 30 countries, Zentiva is united by its commitment to the individuals who rely on its products every day. More information can be found at www.zentiva.com.